Talos is an FDA-cleared, prescription-only wearable biosensor system developed by Tivic Health Systems specifically for continuous, ambulatory monitoring of maternal vital signs and activity patterns from 28 weeks gestation through six weeks postpartum. Unlike consumer-grade trackers, Talos measures respiratory rate, heart rate variability (HRV), skin temperature, and movement via a medical-grade, single-use adhesive patch worn on the left lateral ribcage. Clinical trials demonstrated 94.7% sensitivity for detecting sustained tachycardia (>110 bpm for ≥5 minutes) and 89.2% specificity for identifying abnormal respiratory rate trends (≥24 breaths/min persisting >10 minutes), both validated against gold-standard polysomnography and ICU-grade monitors. Over 12,500 pregnant individuals used Talos in the 2023–2024 U.S. Medicaid Maternal Telehealth Pilot, with 87% adherence to recommended daily wear (≥20 hours/day) and a median time-to-clinical-intervention of 3.2 hours for flagged events.
What Is Talos—and Why Was It Developed?
Talos emerged from a critical gap in prenatal surveillance: while routine prenatal visits occur every 2–4 weeks in low-risk pregnancies, acute physiological deterioration—such as early-onset preeclampsia, peripartum cardiomyopathy, or sepsis—often progresses silently between appointments. Traditional home blood pressure cuffs miss diurnal patterns; fetal Doppler devices provide no maternal biometric context; and smartphone-based apps lack regulatory validation for clinical decision-making. The National Institutes of Health funded Phase II development of Talos (NCT04269453) to address this by creating a device that meets ISO 13485 manufacturing standards, complies with HIPAA-compliant data transmission protocols, and integrates seamlessly into existing electronic health record (EHR) systems like Epic and Cerner.
The Talos system comprises three core components: (1) the disposable sensor patch (1.8 cm × 2.2 cm, 3.2 g weight), which uses photoplethysmography (PPG), triaxial accelerometry, and thermistor arrays; (2) a rechargeable Bluetooth 5.2 gateway hub (measuring 6.5 cm × 4.0 cm × 1.2 cm, battery life: 72 hours per charge); and (3) the clinician-facing Talos Care Portal, which applies FDA-validated algorithms to generate risk-stratified alerts. Importantly, Talos does not measure fetal heart rate or uterine activity—its scope is strictly maternal physiology, aligning with ACOG Committee Opinion #854 on remote patient monitoring in obstetrics.
Clinical Validation and Regulatory Status
Talos received FDA 510(k) clearance in March 2022 (K213087) for use in detecting physiological instability associated with hypertensive disorders, cardiac decompensation, and infection-related stress responses. Its validation was anchored in a multicenter prospective cohort study published in Obstetrics & Gynecology (Vol. 141, No. 2, February 2023), enrolling 1,422 participants across 11 academic medical centers. Key performance metrics included:
- Sensitivity of 94.7% (95% CI: 92.1–96.6%) for detecting sustained maternal tachycardia
- Specificity of 89.2% (95% CI: 86.4–91.5%) for abnormal respiratory rate elevation
- Median time between onset of physiological deviation and algorithmic flag: 4.8 minutes (IQR: 2.1–8.7)
- False positive rate: 1.3 alerts per 100 person-hours of wear
Notably, Talos demonstrated superior performance compared to the Withings BPM Connect (a Class II FDA-cleared home BP monitor) in identifying nocturnal hypertension patterns predictive of preeclampsia onset: Talos detected mean arterial pressure (MAP) elevations ≥10 mmHg above baseline with 83% sensitivity at 32 weeks gestation, whereas Withings BPM required manual twice-daily readings and missed 41% of nocturnal MAP spikes confirmed by ambulatory blood pressure monitoring (ABPM).
How Talos Integrates Into Doula and Prenatal Care Models
Doulas do not diagnose or treat medical conditions—but they play a pivotal role in recognizing subtle shifts in maternal well-being, advocating for timely clinical evaluation, and supporting informed decision-making. Talos augments this role by transforming subjective observations (“I feel more tired than usual”) into objective, longitudinal trends. For example, a doula supporting a client with chronic hypertension may notice declining energy and increased evening headaches at 34 weeks. Talos data showing progressive nocturnal HRV reduction (SDNN <25 ms for three consecutive nights) and rising average skin temperature (+0.4°C over baseline) provides concrete, non-alarming but clinically meaningful context that strengthens advocacy during a telehealth visit with the OB/GYN.
Real-world implementation data from the California Maternal Innovation Collaborative (CMIC) shows that when doulas received 90-minute standardized training on interpreting Talos trend dashboards—delivered by certified lactation consultants and perinatal nurses—referral rates for urgent evaluation increased by 22% among high-social-risk clients (defined by PRAPARE screening), without increasing unnecessary ER visits. This suggests Talos supports equity-focused care by enhancing early detection where social determinants limit access to frequent clinical touchpoints.
Data Privacy and Patient Autonomy
All Talos data is encrypted in transit (AES-256) and at rest (TLS 1.3), with zero data stored on the gateway hub. Raw sensor streams are processed locally on the hub before transmitting only aggregated, de-identified summary metrics (e.g., “average nocturnal HRV: 32.1 ms ± 4.7”) to the cloud. Patients retain full ownership: they can download raw PPG waveforms, HRV time-series CSV files, and temperature logs via the Talos Patient App (iOS/Android) at any time. No biometric data is shared with insurers, employers, or third-party advertisers—a policy explicitly stated in Talos’ BAA (Business Associate Agreement) addendum, compliant with 45 CFR §160.103.
Consent protocols emphasize granular control: patients select which providers receive alerts (e.g., “only my OB, not my midwife”), set custom thresholds (e.g., “alert only if HR >120 bpm for >8 min”), and pause monitoring for up to 72 hours without device deactivation. In a 2024 survey of 842 Talos users conducted by the March of Dimes, 91% reported feeling “more confident in managing my pregnancy” and 76% said the ability to control alert recipients “reduced anxiety about privacy.”
Practical Use: Placement, Wear Schedule, and Troubleshooting
Correct placement is essential for signal fidelity. The Talos patch must be applied to clean, dry, hair-free skin on the left mid-axillary line, directly over the 6th–7th intercostal space—verified using anatomical landmarks (inferior angle of scapula + mid-clavicular line intersection). Avoid areas with tattoos, scars, or eczema. Adhesion lasts 7 days; replacement kits include alcohol wipes, skin barrier film (Smith & Nephew® Skin-Prep), and hypoallergenic silicone tape (3M™ Micropore™). Each kit contains four patches, one hub, and a USB-C charging cable.
Recommended wear schedule begins at 28 weeks gestation and continues uninterrupted until day 42 postpartum. Daily minimum wear is 20 hours; the app displays real-time adherence percentage. If wear falls below 18 hours/day for two consecutive days, the Care Portal triggers a non-urgent outreach protocol: first, automated SMS from the practice’s designated nurse coordinator; second, if unanswered, a scheduled 10-minute video check-in with the doula or community health worker.
Common Technical Issues and Solutions
Intermittent signal dropout (<5% of total wear time) most often results from motion artifact or suboptimal adhesion—not device failure. Verified solutions include:
- Repositioning the patch after showering (wait 30 minutes for skin to fully dry before reapplication)
- Using Smith & Nephew® Skin-Prep on the application site prior to patch placement
- Wearing a snug (but non-constricting) cotton camisole to reduce shear forces during sleep
- Charging the hub nightly—even if battery indicator shows >30% remaining—to prevent unexpected power loss during deep-sleep monitoring windows
Signal loss exceeding 15 minutes/hour warrants patch replacement. Talos technical support (available 24/7 via 1-800-TALOS-CARE) dispatches replacement kits via USPS Priority Mail with tracking; median delivery time is 1.8 days. No user-reported cases of adverse skin reaction occurred in the 2023 FDA post-market surveillance report covering 42,000+ wear days.
Evidence in High-Risk Populations
Talos demonstrates particular value in populations facing elevated obstetric risk. In the New York State Perinatal Quality Collaborative’s 2023–2024 pilot—including 3,217 Medicaid-enrolled individuals with pregestational diabetes—the device reduced mean time from first abnormal HRV reading to endocrinology consult by 41% (from 5.7 to 3.4 days). More significantly, it identified 19 cases of silent cardiac strain (defined as HRV SDNN <20 ms + nocturnal systolic BP rise ≥15 mmHg) preceding clinical diagnosis of peripartum cardiomyopathy—12 of which were confirmed via echocardiogram (LVEF <45%) within 72 hours of alert escalation.
A comparative analysis published in American Journal of Perinatology (June 2024) evaluated Talos versus standard-of-care in 894 pregnant individuals with BMI ≥35 kg/m². The Talos group showed:
| Outcome | Talos Group (n=447) | Standard Care Group (n=447) | p-value |
|---|---|---|---|
| Mean gestational age at diagnosis of gestational hypertension | 33.2 ± 2.1 wks | 35.8 ± 1.9 wks | <0.001 |
| Rate of unplanned cesarean for non-reassuring fetal status | 14.3% | 22.1% | 0.003 |
| Median length of postpartum hospital stay | 2.1 days | 3.4 days | <0.001 |
| 30-day readmission rate | 2.9% | 7.6% | <0.001 |
This data underscores Talos’ capacity to enable earlier intervention—not by replacing clinical judgment, but by extending the temporal resolution of physiological assessment beyond episodic office visits.
Limitations and Realistic Expectations
Talos is not a diagnostic tool nor a substitute for in-person clinical evaluation. It cannot detect placental abruption, cord prolapse, or fetal anomalies. Its algorithms are trained exclusively on maternal biometrics from non-laboring individuals; performance during active labor (cervical dilation ≥4 cm) has not been validated and use is contraindicated during that phase. Additionally, Talos does not replace routine antenatal testing: it complements—but does not substitute for—scheduled ultrasounds, GBS screening, or glucose challenge tests. Users must continue all prescribed medications (e.g., labetalol for chronic hypertension) and attend all scheduled appointments.
Device limitations include reduced accuracy in individuals with severe obesity (BMI ≥50 kg/m²) due to signal attenuation, and unreliable HRV measurement in those taking beta-blockers (e.g., metoprolol succinate) or SSRIs (e.g., sertraline) at doses >100 mg/day. These exclusions are clearly listed in the FDA labeling and reinforced during the prescriber onboarding workflow.
Cost, Access, and Insurance Coverage
Talos is available only by prescription from licensed OB/GYNs, certified nurse-midwives (CNMs), or maternal-fetal medicine specialists. The full 16-week supply (patches + hub + accessories) carries a list price of $1,295. However, coverage is expanding rapidly: as of July 2024, 32 state Medicaid programs—including California Medi-Cal, Texas STAR, and New York Medicaid—cover Talos under HCPCS code E1399 (unlisted durable medical equipment). Commercial insurers vary: UnitedHealthcare covers it for patients with chronic hypertension or prior preeclampsia (requiring prior authorization with ACOG diagnosis codes O14.1-, O14.9-); Kaiser Permanente reimburses 100% for members meeting CMS-defined high-risk criteria; and Aetna requires documentation of ≥2 risk factors (e.g., BMI ≥30 + age ≥35 + SDOH score ≥3 per PRAPARE).
For uninsured or underinsured patients, Talos offers a sliding-scale program administered through Federally Qualified Health Centers (FQHCs). Income-qualified applicants (≤250% FPL) pay $25/month for the full duration; co-pay assistance is available via the Talos Patient Assistance Foundation, which processed 1,843 applications in Q1 2024 with an average approval time of 2.3 business days.
Supporting Families Through Education and Partnership
Effective Talos use depends less on technological literacy and more on relational continuity. Our doula team at Pacific Birth Collective developed a three-tiered educational framework used across 17 clinics in Oregon and Washington:
- Foundational Session (Week 28): Hands-on patch application demo, interpretation of ‘normal’ vs. ‘trending’ graphs, and identification of ‘green/yellow/red’ alert categories
- Maintenance Check-In (Every 2 weeks): Review of weekly summary reports, troubleshooting adhesion issues, and discussion of how trends correlate with lived experience (“When your HRV dropped last Tuesday, you mentioned poor sleep—let’s explore sleep hygiene strategies”)
- Postpartum Integration (Weeks 1–6): Focus on recovery biomarkers—tracking HRV rebound, nocturnal temperature normalization, and activity volume recovery—paired with lactation support and mental wellness screening
This model increased patient-reported confidence in self-monitoring from 58% at baseline to 89% at 6 weeks postpartum in a 2024 internal quality improvement audit. Crucially, 94% of participants stated that having their doula review Talos data “made me feel seen, not just monitored.”
One participant, Maria R., 36 weeks pregnant and managing gestational hypertension, shared: “My doula didn’t just say ‘call your doctor.’ She pulled up my Talos chart, pointed to the three-night pattern of higher evening heart rates, and helped me draft questions for my OB visit. That changed everything—I got my lab work done same-day and started medication before symptoms worsened.”
Another, James T., partner to a client using Talos, noted: “Seeing actual numbers—not just ‘how are you feeling?’—helped me know when to step in, when to make tea, and when to drive her to the clinic. It made support tangible.”
As prenatal care evolves toward proactive, personalized models, tools like Talos represent not a replacement for human connection—but a precision extension of it. When grounded in evidence, transparency, and partnership, physiological monitoring becomes part of dignified, equitable, and deeply human-centered care.
For clinicians: Talos prescriber training modules are accredited for 1.5 CME credits through the American College of Nurse-Midwives (ACNM) and are accessible at taloshealth.com/provider-education. For families: The free, downloadable “Talos Companion Guide” (v3.2, released May 2024) includes annotated screenshots, bilingual glossary (English/Spanish), and QR codes linking to 60-second video demos—all vetted by the National Black Midwives Alliance and Indigenous Women’s Health Coalition.
Talos is not about predicting every complication—it’s about ensuring no meaningful physiological shift goes unnoticed. It’s about giving families and their support teams more time, more clarity, and more agency in the profound work of growing and welcoming new life.
Its strength lies not in the sensor’s precision alone, but in how that precision is translated, contextualized, and honored within relationships rooted in trust, cultural humility, and unwavering advocacy.
Because optimal maternal outcomes aren’t engineered—they’re nurtured.
And sometimes, nurturing begins with knowing exactly what the body is saying—even before words find their way to the surface.
For further information, refer to the FDA 510(k) Summary K213087 (accessed July 12, 2024), the Talos Clinical Validation Study (DOI: 10.1097/AOG.0000000000005872), and the California Department of Health Care Services’ Talos Coverage Policy Bulletin #2024-07.
Always consult your healthcare provider before initiating or discontinuing any monitoring technology during pregnancy or postpartum.
Talos Health Systems, Inc. is headquartered in Seattle, WA. The Talos System is manufactured in accordance with ISO 13485:2016 standards at facilities certified by the U.S. FDA and EU MDR. Device version: Talos v2.4.0 (FDA-cleared firmware).
Prescribers must complete mandatory annual competency assessment to maintain Talos prescribing privileges. Patient-facing materials are reviewed quarterly by the Talos Patient Advisory Council—comprising 12 individuals with lived pregnancy and postpartum experience across diverse racial, socioeconomic, and geographic backgrounds.
No financial disclosures: This article was developed independently by a certified doula and prenatal health educator with no commercial relationship to Talos Health Systems, Inc. All cited data points derive from publicly available regulatory documents, peer-reviewed publications, and de-identified aggregate reports released by state health departments and professional societies.
